Skye Bioscience to Present at Upcoming Investment Conferences in April

Rhea-AI Summary

Skye Bioscience, Inc. (OTCQB: SKYE) announced that CEO Punit Dhillon will present a corporate overview at the upcoming Sequire Cannabis Investor Conference on April 20, 2021, at 12:30 PM EST, and at the Planet Microcap Showcase on April 22, 2021, at 10:30 AM EST. The company is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other unmet medical needs. Their lead molecule shows potential for lowering intraocular pressure in glaucoma patients, outperforming current treatments. For more details, visit www.skyebioscience.com.

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will present a virtual corporate overview at the Sequire Cannabis Investor Conference and Planet Microcap Showcase next week. Details are as follows:

Sequire Cannabis Investor Conference
Date: April 20, 2021
Time: 12:30 PM EST; Track 1
Registration Link:  https://bit.ly/3aeOPi2

Planet Microcap Showcase
Date: April 22, 2021
Time: 10:30 AM EST; Track 1
Registration Link:  https://bit.ly/3mLO9pa

About Skye Bioscience, Inc.
Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to the current standard of care. For more information, please visit: www.skyebioscience.com.

CONTACT
Karam Takhar
VP, Corporate Development & Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

FAQ

When will Skye Bioscience present at the Sequire Cannabis Investor Conference?

Skye Bioscience will present at the Sequire Cannabis Investor Conference on April 20, 2021, at 12:30 PM EST.

What is the focus of Skye Bioscience's presentation?

The presentation will focus on Skye Bioscience's development of synthetic cannabinoid-derived molecules for treating glaucoma and other unmet medical needs.

Where can I find the registration link for the Sequire Cannabis Investor Conference?

You can register for the Sequire Cannabis Investor Conference at https://bit.ly/3aeOPi2.

What is the date and time for the Planet Microcap Showcase presentation?

The Planet Microcap Showcase presentation will take place on April 22, 2021, at 10:30 AM EST.

How does Skye Bioscience's lead molecule perform in treating glaucoma?

Skye Bioscience's lead molecule has shown potential in preclinical studies to lower intraocular pressure in glaucoma patients, with efficacy superior to the current standard of care.